Diagnosis and Management of Infantile Hemangioma

Table 24. Adverse effects in case series of propranolol to treat IH (continued)
Number of
Studies (#
Intervention
Harm/Adverse Event
Participants
With Harm/Total
Participants)
Oral Propranolol 2-3
mg/kg/day
†† Oral Propranolol 1-4
mg/kg/day
Topical Propranolol 0.5-3%
Reported
Rates
Across
Studies
Cold extremities 16,172 2 (64/206) 3%-36%
Nocturnal restlessness 172 1 (39/174) 22%
Daytime sleepiness/Inactivity 172 1 (28/174) 16%
Gastrointestinal symptoms 172 1 (12/174) 7%
Agitation 16 1 (2/32) 6%
Insomnia 16 1 (2/32) 6%
Restlessness/Increased daytime activity 172 1 (9/174) 5%
Hypotension 16,172 2 (7/206) 3%
Asthma/Wheezing 16,172 2 (18/206) 3%
Nightmares 16 1 (1/32) 3%
Sweating 16 1 (1/32) 3%
Feeding difficulties 172 1 (3/174) 2%
Ulceration (onset/worsening) 172 1 (4/174) 2%
Breath holding spells 172 1 (2/174) 1%
Somnolence 185,195 2 (5/83) 6%-6.7%
Hypoglycemia 185 1 (1/53) 2%
Hypotension 185 1 (1/53) 2%
Profound mottling of extremities 185 1 (1/53) 2%
Severe bradycardia 185 1 (1/53) 2%
Cold extremities 195 1 (3/30) 10%
Bronchospasm 195 1 (3/30) 10%
Transaminase increase 195 1 (1/30) 3.3%
Skin changes (redness, rash, itching, 2 (9/249) 1.96%-4%
erosion, eczema) 197,198,204
Ulceration 204 1 (5/148) 3%
63